AD/PD 2025 Conference

Dates: March 5-9, 2025 Location: Vienna International Centre (VIC), Vienna, Austria Organizer: Kenes Group Website: [adpd.kenes.com](https://adpd.kenes.com)

Overview

AD/PD 2025 was held in Vienna, Austria, continuing the tradition of bringing together Alzheimer's and Parkinson's disease researchers in a unique integrated format. The conference is distinguished by its focus on the mechanistic links between AD and PD, exploring common pathways and shared therapeutic approaches["@adpd2025"].

Key Themes

Alzheimer's Disease Research

Amyloid and Tau Biology

Dates: March 5-9, 2025 Location: Vienna International Centre (VIC), Vienna, Austria Organizer: Kenes Group Website: [adpd.kenes.com](https://adpd.kenes.com)

Overview

AD/PD 2025 was held in Vienna, Austria, continuing the tradition of bringing together Alzheimer's and Parkinson's disease researchers in a unique integrated format. The conference is distinguished by its focus on the mechanistic links between AD and PD, exploring common pathways and shared therapeutic approaches["@adpd2025"].

Key Themes

Alzheimer's Disease Research

Amyloid and Tau Biology

• [Amyloid-beta](/proteins/amyloid-beta) aggregation mechanisms and toxic species identification
• [Tau](/proteins/tau) phosphorylation patterns and spread patterns
• Amyloid-Tau interaction effects on neurodegeneration
• Post-translational modifications affecting protein aggregation

Neuroinflammation

• Microglial biology in AD pathogenesis
• Complement cascade involvement in synaptic dysfunction
• Astrocyte reactivity and neurotransmitter modulation
• Peripheral immune system interactions with CNS

Biomarkers

• Fluid biomarkers (p-tau, NfL, GFAP) clinical implementation
• PET imaging advances for amyloid, tau, and neuroinflammation
• Digital biomarkers for remote monitoring
• Multimodal biomarker panels for disease staging

Clinical Trials

• Anti-amyloid antibody outcomes and real-world data
• Tau-targeted therapy progress
• Disease-modifying approaches in early AD
• Prevention trials in at-risk populations

Parkinson's Disease Research

Alpha-Synuclein

• Alpha-synuclein (/proteins/alpha-synuclein) aggregation mechanisms
• [Prion-like spreading](/entities/prion-like-spreading) of pathological species
• Strain diversity and clinical phenotypes
• Antibody trials targeting alpha-synuclein

Genetic Forms

• [LRRK2](/entities/lrrk2) (/genes/lrrk2) variants and kinase inhibition
• [GBA](/entities/gba) (/genes/gba) mutations and Gaucher disease link
• SNCA (/genes/snca) multiplication and overexpression
• PARKIN (/genes/parkin) and mitochondrial dysfunction

Movement Disorders

• Deep brain stimulation advances
• Levodopa-carbidopa intestinal gel outcomes
• Novel dopaminergic agents
• Non-motor symptoms management

Cross-Disease Topics

Shared Mechanisms

• Neuroinflammation as common pathway
• Mitochondrial dysfunction in both AD and PD
• Oxidative stress and protein aggregation
• Lysosomal/autophagy impairment

Common Biomarkers

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) as progression marker
• [p-tau217](/biomarkers/p-tau-217) in Lewy body disease
• Alpha-synuclein seeding assays in AD
• Neuroinflammation markers across diseases

Combination Therapy Approaches

• Multi-target therapeutic strategies
• Sequential intervention timing
• Personalized medicine based on biomarker profiles

Notable Sessions

Integrated Symposia

• "Alpha-Synuclein and Amyloid: Shared Pathways, Shared Therapies"
• "Neuroinflammation in AD and PD: Common Mechanisms"
• "Biomarker Convergence: What Tells Us About Both Diseases"

Focused Workshops

• Tau Imaging Workshop — Advanced PET analysis methods
• Alpha-Synuclein Seed Assay — Clinical implementation challenges
• Clinical Trial Design — Optimizing for disease modification

Hot Topics

• Results from Phase 3 anti-amyloid trials
• LRRK2 inhibitor clinical outcomes
• α-synuclein antibody trial results
• Genetic risk modifier studies

Venue: Vienna International Centre

About the Venue

The Vienna International Centre (VIC) is one of the world's major conference centers, hosting numerous scientific meetings annually. The venue offers state-of-the-art facilities for scientific presentations.

Vienna Neuroscience Community

Vienna is home to several leading research institutions:

• Medical University of Vienna — Major AD/PD research programs
• University of Vienna — Basic neuroscience research
• Austrian Academy of Sciences — Neurological research
• IMP Vienna — Molecular biology research

About Vienna

Vienna combines historic charm with scientific excellence:

• Historic center (Innere Stadt) is a UNESCO World Heritage site
• Excellent public transportation system
• Central European location accessible from many countries
• Rich cultural offerings including music, art, and architecture

Related Conferences

• [AD/PD 2026](/events/adpd-2026) — Vienna, Austria
• [AAIC 2025](/events/aaic-2025) — San Diego, USA
• [MDS Congress](/events/mds-2026)

See Also

• [Conference Index](/events/conference-index)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau)

References